Marker Therapeutics ( (MRKR) ) has released its Q3 earnings. Here is a breakdown of the information Marker Therapeutics presented to its investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on developing novel T cell-based immunotherapies for treating hematological malignancies and solid tumors. The company recently released its earnings report for the quarter ending September 30, 2025, highlighting several financial and operational metrics. Marker Therapeutics reported a net loss of $1.99 million for the quarter, with total revenues of $1.23 million primarily from grant income. The company’s operating expenses totaled $3.37 million, driven by research and development costs and general administrative expenses. Despite the losses, Marker Therapeutics has secured significant grant funding to support its clinical trials and product development efforts. Looking ahead, the company remains focused on advancing its clinical programs and exploring additional funding opportunities to sustain its operations beyond 2026.